246 related articles for article (PubMed ID: 28832236)
1. ICUS/CCUS/CHIP: basics & beyond.
Jain M; Tripathi A
Expert Rev Hematol; 2017 Oct; 10(10):915-920. PubMed ID: 28832236
[TBL] [Abstract][Full Text] [Related]
2. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP).
Malcovati L; Cazzola M
Hematology Am Soc Hematol Educ Program; 2015; 2015():299-307. PubMed ID: 26637737
[TBL] [Abstract][Full Text] [Related]
3. ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications.
Valent P
Pathobiology; 2019; 86(1):30-38. PubMed ID: 29860246
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lower-risk myelodysplastic syndrome.
Choi EJ; Cho YU; Hur EH; Park HS; Choi Y; Lee JH; Lee KH; Kim M; Hwang SH; Jang S; Park CJ; Seo EJ; Lee JH
Br J Haematol; 2022 Aug; 198(4):703-712. PubMed ID: 35612271
[TBL] [Abstract][Full Text] [Related]
5. How I investigate Clonal cytogenetic abnormalities of undetermined significance.
Tang G; Medeiros LJ; Wang SA
Int J Lab Hematol; 2018 Aug; 40(4):385-391. PubMed ID: 29624895
[TBL] [Abstract][Full Text] [Related]
6. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice.
DeZern AE; Malcovati L; Ebert BL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():400-410. PubMed ID: 31099654
[TBL] [Abstract][Full Text] [Related]
7. Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS-type molecular findings compared to CCUS without dysplasia.
Jajosky AN; Sadri N; Meyerson HJ; Oduro KA; Kelkar A; Fitzgerald B; Tomlinson B; Moore EM; Beck RC
Eur J Haematol; 2021 Apr; 106(4):500-507. PubMed ID: 33386622
[TBL] [Abstract][Full Text] [Related]
8. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
Ganguly BB; Banerjee D; Agarwal MB
Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
[TBL] [Abstract][Full Text] [Related]
9. Targeted NGS on sequential bone marrow biopsies aids in the evaluation of cytopenias and monocytosis and documents clonal evolution-a proof of principle study.
Nann D; Rau A; Mahmutovic L; Steinhilber J; Meca V; Federmann B; Vogel W; Bonzheim I; Quintanilla-Martinez L; Fend F
Virchows Arch; 2023 Dec; 483(6):835-845. PubMed ID: 37610626
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic and prognostic role of flow cytometry in idiopathic and clonal cytopenia of undetermined significance (ICUS/CCUS): A single-center analysis of 79 patients.
Dimopoulos K; Hansen OK; Sjö LD; Saft L; Schjødt IM; Werner Hansen J; Grønbaek K
Cytometry B Clin Cytom; 2020 May; 98(3):250-258. PubMed ID: 31479199
[TBL] [Abstract][Full Text] [Related]
11. [Diagnostics in unclear cytopenia-How and when do we screen for clonal hematopoiesis?].
Haferlach C; Heuser M
Inn Med (Heidelb); 2022 Nov; 63(11):1141-1147. PubMed ID: 36121473
[TBL] [Abstract][Full Text] [Related]
12. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.
Kwok B; Hall JM; Witte JS; Xu Y; Reddy P; Lin K; Flamholz R; Dabbas B; Yung A; Al-Hafidh J; Balmert E; Vaupel C; El Hader C; McGinniss MJ; Nahas SA; Kines J; Bejar R
Blood; 2015 Nov; 126(21):2355-61. PubMed ID: 26429975
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?
Bejar R
Curr Hematol Malig Rep; 2015 Sep; 10(3):282-91. PubMed ID: 26126599
[TBL] [Abstract][Full Text] [Related]
14. Where Does Morphology Fit in Myelodysplastic Syndrome Diagnosis in the Era of Molecular Testing?
Giagounidis A; Haase S
Hematol Oncol Clin North Am; 2020 Apr; 34(2):321-331. PubMed ID: 32089213
[TBL] [Abstract][Full Text] [Related]
15. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
Steensma DP; Bejar R; Jaiswal S; Lindsley RC; Sekeres MA; Hasserjian RP; Ebert BL
Blood; 2015 Jul; 126(1):9-16. PubMed ID: 25931582
[TBL] [Abstract][Full Text] [Related]
16. LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome.
Kaastrup K; Gillberg L; Mikkelsen SU; Ørskov AD; Schöllkopf C; Mortensen BK; Porse B; Hansen JW; Grønbæk K
Clin Epigenetics; 2023 May; 15(1):91. PubMed ID: 37237325
[TBL] [Abstract][Full Text] [Related]
17. From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?
Bewersdorf JP; Ardasheva A; Podoltsev NA; Singh A; Biancon G; Halene S; Zeidan AM
Blood Rev; 2019 Sep; 37():100587. PubMed ID: 31400824
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis.
Osman A; Patel JL
Clin Chem; 2021 Aug; 67(8):1062-1070. PubMed ID: 34263288
[TBL] [Abstract][Full Text] [Related]
19. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface.
Wimazal F; Fonatsch C; Thalhammer R; Schwarzinger I; Müllauer L; Sperr WR; Bennett JM; Valent P
Leuk Res; 2007 Nov; 31(11):1461-8. PubMed ID: 17507091
[TBL] [Abstract][Full Text] [Related]
20. Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients.
Schroeder T; Ruf L; Bernhardt A; Hildebrandt B; Aivado M; Aul C; Gattermann N; Haas R; Germing U
Ann Oncol; 2010 Nov; 21(11):2267-2271. PubMed ID: 20439346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]